Tranexamic Acid Powder CAS 1197-18-8

Tranexamic acid, also known as hemostatic cyclic acid, coagulation acid, antifibrinolytic cyclic acid, also known as tranexic acid (rare), etc., is an organic compound with a chemical formula of C8H15NO2 and a molar mass of 157.21 g/mol. Its appearance is white crystalline powder, easily soluble in water and glacial acetic acid, almost insoluble in ethanol and acetone, and the pH value of 5% aqueous solution is 7.0~8.0. Tranexamic acid has amino acid reactions, such as the aqueous solution and ninhydrin solution are slightly heated, and the solution changes from colorless to blue-purple; It is orange-red with ferric chloride test solution.

Research shows that tranexamic acid can safely and reliably reduce mortality in trauma hemorrhage patients. In light of this, tranexamic acid, an inexpensive, non-patented drug, has been included in the WHO Model List of Essential Medicines and will be widely used in high-, middle-, and low-income countries around the world.

Research shows that the likelihood of progressive bleeding and the mortality rate may be reduced in patients with traumatic brain injury receiving tranexamic acid. Although neither of these studies has drawn very clear conclusions, they still suggest that tranexamic acid may improve the prognosis of traumatic brain injury, which will lay the foundation for subsequent research, such as the upcoming CRASH-3 study, which will recruit up to 10,000 patients with traumatic brain injury and provide reliable evidence for the efficacy of tranexamic acid in improving mortality and disability rates.

Tranexamic acid can significantly reduce blood loss in women with menorrhagia. A Cochrane systematic review evaluating the treatment of menorrhagia with antifibrinolytic drugs (primarily tranexamic acid) indicates that antifibrinolytic agents can reduce blood loss more in women with menorrhagia compared to placebo or other treatments, without increasing the incidence of adverse reactions. The U.S. Food and Drug Administration (FDA) has approved the oral tablets of tranexamic acid as a treatment for women with severe menorrhagia since November 13, 2009.

1. Trauma or surgical bleeding of the prostate, urethra, lungs, brain, uterus, adrenal glands, thyroid, liver and other organs rich in plasminogen activators.

2. Used as an antagonist of fibrinolytic agents, such as tissue plasminogen activator (t-PA), streptokinase, and urokinase.

3. Fibrinolytic hemorrhage caused by induced abortion, early placental abruption, stillbirth, and amniotic fluid embolism.

4. Heavy menorrhagia with increased local fibrinolysis, anterior chamber bleeding and severe epistaxis.

5. It is used to prevent or reduce bleeding after tooth extraction or oral surgery in hemophilia patients with factor VIII or factor IX deficiency.

6. For mild bleeding caused by intracranial aneurysm rupture, such as subarachnoid hemorrhage and intracranial aneurysm hemorrhage, this product is better than other antifibrinolytic drugs, but attention must be paid to the risk of cerebral edema or cerebral infarction. For patients with severe surgical indications, this product can only be used as an adjuvant drug.

7. It is used to treat hereditary angioedema, which can reduce the number and severity of its attacks.

8. Active bleeding in patients with hemophilia.

9. It has a definite effect on melasma.

Intravenous infusion: For general adults, 0.25 to 0.5g per dose, and when necessary, 1 to 2g daily, administered in 1 to 2 doses. The dosage may be adjusted appropriately according to age and symptoms, or as directed by a physician.

To prevent bleeding before and after surgery, the above dosage may be used as a reference. For treating bleeding caused by primary fibrinolysis. The dosage may be increased as appropriate.

We provide first-hand sources; guaranteeing competitive prices and quality. After you place an order, we can arrange shipment on the same day, ensuring product quality and stable delivery, allowing us to achieve a win-win partnership.